RD.06.SPR.[ZIP_CODE]  Protocol summary  
Protocol V03-06Mar2017  
 
 
Page 1 of 10 
Final v ersion dated 10 March  2017 A Multi -Center, Randomized, Double -Blind, Parallel- Group Vehicle Controlled Study To Compare The 
Efficacy And Safety Of CD5789 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris  
RD.06.SPR.[ADDRESS_170019] NUMBER :  2016-002860-15  
IND NUMBER : 111091 
1/ CLINIC AL TRIAL OB J EC TIV ES   
The clinical trial objectives are to assess the efficacy and safety of CD5789 50 µg/g cream applied once 
daily for 12 weeks in subjects with moderate  facial and truncal acne vulgaris.  
2/ ST UDY DES IG N  
Phase 3, multi-center, randomized, double blind, vehicle controlled study comparing CD5789 cream 
applied once daily in the evening for 12 weeks versus its vehicle.  
Group 1: CD5789 50μg/g cream  
Group 2: Vehicle c ream  
Subjects treated once daily for 12 weeks and evaluated at Baseline, Weeks  1, 2, 4, 8 and 12/Early 
Termination . 
3/ CLINIC AL ST UDY DURAT IO N  
The planned clinical trial duration (from FSI to LSO) is approximately 26 months.  
The planned duration of recruitment (i.e. From FSI to LSI) is approximately 23 months.  
4/ DURAT IO N O F SU B J EC T PARTICIPATIO N  & SU B J EC TS ’ VISITS  
Clinical trial participation for each subject is approximately 14 weeks ( screening period of 14 days with a 
time window of + 3 days followed by 12 weeks of study treatment ±5 days).  
 
5/ TO T AL NUMBE R O F SUBJE C TS  (PLANNE D ): 
Approximately 1500 subjects will be screened in order to obtain 1200 randomized subjects (600 per 
treatment arm).  
6/NUMBE R O F CLINICAL T RIAL C EN TER S  (PLANNE D ):  
Approximately 160 sites 
7/ REG IO N (S) / CO UNT RY (IES) INVO LVE D (PLANNE D ):  
[LOCATION_002], Puerto Rico, Europe, Canada and Russia  
8/ INCLUSIO N /EXCLUSIO N CR ITER IA  
8.1/ Inclusion criteria:  
1. The subject is a male or female, 9 years of age and  older at the Screening visit.  
 For Russia : The subject is a male or female, [ADDRESS_170020] has a facial acne severity grade of 3 (moderate) on the Investigator Global Assessment 
(IGA) scale at Screening and Baseline.  
3. The subject has a minimum of [ADDRESS_170021] has a truncal acne severity grade of 3 (moderate) on the Physician Global assessment (PGA) scale at Screening and Baseline visits on trunk (shoulders, upper back and upper anterior chest) reachable for self -application of study drug by [CONTACT_423] (optional criterion for subject 
between 9 and 11 years  of age).  
5. The subject has a minimum of 20 inflammatory lesions and 20 non- inflammatory lesions but no 
more than 100 non- inflammatory lesion counts on the trunk (shoulders, upper back and upper 
anterior chest) reachable to self -application of study drug by [CONTACT_148293] 
(optional c riterion for subject between 9 and 11 years of age).  
6. The subject is a female of non -childbearing potential (pre -menarcheal or postmenopausal [absence 
of menstrual bleeding for 1 year prior to Screening, without any other medical reason], 
hysterectomy or bilateral oophorectomy).  
RD.06.SPR.[ADDRESS_170022] is a female of childbearing potential:  
7.1. With a negative urine pregnancy test (UPT) at Screening and Baseline visits,  
7.2. Who has been strictly abstinent for [ADDRESS_170023] study drug application,  
OR 
 Who agrees to use an effective and approved contraceptive method(s) for the duration of the study 
and at least [ADDRESS_170024] study drug application. An effecti ve method of contraception is 
defined as:  
7.2.a.   bilateral tubal ligation;  
7.2.b. approved combined oral contraceptives (estrogens and progesterone), implanted or 
injectable contraceptives, or hormonal contraceptive vaginal rings with a stable dose for at 
least 1 m onth prior to the Baseline visit;  
7.2.c.   hormonal intra uterine device (IUD) inserted at least 1 month prior to the Baseline visit;  
7.2.d. vasectomized partner for at least 3 months prior to the Baseline visit.  
8. If a female of childbearing potential uses combined oral  contraceptives approved as acne treatments 
(e.g., Ortho Tri -Cyclen®, Yaz®, Diane -35®), the dose should be stable for at least 6 months prior to 
the Baseline visit.  
9. For a pre -menstrual female who begins menses during the study:  
9.1. Agrees to be strictly absti nent for the duration of the clinical trial and at least [ADDRESS_170025] study drug application,  
OR 
9.2. Agrees to use an effective and approved contraceptive method(s) for the duration of the study and 
at least [ADDRESS_170026] study drug application and agrees to undergo pregnancy tests. An 
effective method of contraception is defined as approved combined oral contraceptives 
(oestrogens and progesterone), implanted or injectable contraceptives, or hormonal intra -uterine 
device (IUD) or hormonal contraceptive vaginal rings.  
10. The subject is willing and is able to comply with all of the time commitments and procedural 
requirements of the protocol (for subjects who are minors, the parent(s)/legal representative must be also willing and able to comply with study requirements).  
RD.06.SPR.[ADDRESS_170027] agrees to participate in the study, verified by [CONTACT_148294] (ICF) or, for subjects under age of majority, an assent form signed by [CONTACT_423] (if required) in conjunction with an ICF signed by [CONTACT_7071](s)/legal representative at the 
Screening visit before any study procedures.   
 At selected sites : If the subject agrees to participate to study photographs, verified by [CONTACT_148295] a separate approved Informed Consent Form for photos and for subjects under the age of majority, an assent form signed by [CONTACT_148296] a photo ICF signed by [CONTACT_31588](s)/legal representative at the Screening visit. Participation to photo procedures is not 
mandatory to participate in the Study.  
12. The subject is apprised of the Health Insurance Portability and Accountabilit y Ac t (HIPAA), if in the US, 
Personal Information Protection and Electronic Documents Act (PI[INVESTIGATOR_15654]), if in Canada or local privacy 
act if in other countries, and is willing to share personal information and data, as verified by [CONTACT_2960] a 
written authorizati on at the Screening visit.  
8.2/ Exclusion criteria:  
1. The subject has severe forms of acne (e.g., acne conglobata, acne fulminans) or secondary acne form (e.g., chloracne, drug- induced acne, etc.).  
2. The subject has more than [ADDRESS_170028] (evaluable area) that may interfere with the study assessments.  
8. The subject has any uncontrolled or serious disease or any medical or surgical condition that may 
either interfere with the interpretation of the trial results and/or put the subject at significant risk 
(according to the Investigator’s judgment)  if the subject takes part to the trial.  
9. The subject has clinically significant abnormal laboratory values according to the Investigator at 
Screening (to be checked prior to Baseline).  
10. The subject has known or suspected allergies or sensitivities to any components of any of the study drugs (see Investigator’s Brochure).  
11. The subject is a female who is lactating.  
12. The subject is a female who intends to conceive a child during the trial or within [ADDRESS_170029] has received, applied, or ingested the following treatments within the specified time frame prior to the Baseline visit as defined in below: 
RD.06.SPR.[ZIP_CODE]  Protocol summary  
Protocol V03-06Mar2017  
 
 
Page 5 of 10 
Final v ersion dated 10 March  2017 Treatment restrictions  
Topi[INVESTIGATOR_148290]:   
Antibiotics  
Benzoyl peroxide  
Azelaic acid  
Zinc 
Corticosteroids  
Other topi[INVESTIGATOR_12969] (including laser)  2 weeks  
Retinoids  4 weeks  
Topi[INVESTIGATOR_148291]:  
Phototherapy devices for acne (e.g., ClearLight )  
Adhesive cleansing strips  (e.g., Pond®, Biore®)  
Cosmetic procedures (i.e., facials, peeling, comedone extraction)  1 week  
Systemic treatment:   
Non-steroidal anti -inflammatory drugs1 2 weeks  
Corticosteroids (except inhaled corticosteroids or intrathecal corticosteroids)  4 weeks  
Antibiotics (except plain penicillin)  4 weeks  
Oral retinoids  6 months  
Immunomodulators, including biologics  6 months  
Note:  
1) During the study , the use of Non-steroidal Anti -Inflammatory  Drugs (NSAIDs) is acceptable for up to 21 day s (cumulativ e) of treatment; 
how ev er, it should be av oided during the [ADDRESS_170030] has been exposed to excessive ultraviolet (UV) radiation within one month prior to the 
Baseline visit or the subject is planning intense UV exposure during the study (i.e., occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.)  
17. The subject is unwilling to refrain from use of prohibited medication during the clinical trial (see Section  
5.5.5  of the protocol v06 March 2017).  
18. The subject is vulnerable (such as deprived from freedom) as defined in Section 1.61 of the ICH 
GCP.  
9/ EFFIC AC Y ASSE SSME NT   
9.1 Efficacy M easurements  
9.1.1 Investigator’s Global Assessment (IGA) / Physician Global Assessment (PGA):  
The IGA/PGA assessments will be performed before the lesion counting.  
The areas defined for IGA assessment are forehead, each cheek, chin and nose.  
The areas defined for PGA assessm ent are shoulders, upper back and anterior chest which are 
accessible to self -application by [CONTACT_423], i.e., the regions that the subject can easily reach and appl y 
the study drug without assistance.  
RD.06.SPR.[ZIP_CODE]  Protocol summary  
Protocol V03-06Mar2017  
 
 
Page 6 of 10 
Final v ersion dated 10 March  2017 Qualified Investigators who successfully complete IGA/PGA training  will evaluate the facial  and 
truncal acne at Screening, Baseline, Week 1, Week 2 , Week 4 , Week 8 and Week 1 2/Early 
Termination visit, according to the following scale:  
Global Assessment Scale (IGA /PGA) ) 
[ADDRESS_170031] Clear  A few scattered comedones and a few small papules.  
2 Mild Easily recognizable; less than half the surface is involved. Some comedones and some 
papules and pustules.  
[ADDRESS_170032] moderate acne on the trunk at Baseline (i.e., who do not have PGA of 3, at least [ADDRESS_170033] 20 non- inflammatory lesions on the trunk): The PGA scale will  be 
used by [CONTACT_148297]. If the subjects 
are treated, the PGA data from these subjects will not be analyzed.  
 
9.1.[ADDRESS_170034] moderate acne on the 
trunk at Baseline  (i.e. who do not have PGA of 3, at least [ADDRESS_170035] 20 non- inflammatory lesions on the trunk): the truncal lesion counts will not be performed.  
It w ill be perfo rmed separately on the face and on the trunk at Screening, Baseline, Week 1, Week 2, 
Week 4, W eek 8 and Week 12/Early Termination visit . 
 
9.1.[ADDRESS_170036].  
Subjects will evaluate their facial acne improvement at the Week 12/ET visit com pared to the start of 
the study.  
 
9.2 Primary Efficacy Endpoint  
The primary efficacy endpoint consists of the following 3 co -primary endpoints:  
1. Success Rate, defined as the percentage of subject s who achieve an IGA score of 1 (Almost Clear) 
or 0 (Clear) and at least a [ADDRESS_170037].06.SPR.[ZIP_CODE]  Protocol summary  
Protocol V03-06Mar2017  
 
 
Page 7 of 10 
Final v ersion dated 10 March  2017 3. Absolute Change in facial inflammatory lesion count from Baseline to Week 12.  
10/ SA FETY  ASSE SSME NT S 
The safety parameters are Adverse Events, local tolerability assessments, laboratory safety tests, physical 
exams and vital signs.  
11/ OTH ER  A S S ES S MEN TS   
11.1 Photographs (at selected sites)  
Facial and truncal photographs will be taken according to a standardized procedure guideline at the 
Baseline, Week 2, 4, 8, and Week 12/Early Termination Visits at selected sites to i llustrate the effect 
observed. 
11.2 Dermatology Life Quality Index (DLQI) / Children’s Dermatology Life Quality Index (C-DLQI)  
Dermatology Life Quality Index (DLQI) and Children’s Dermatology Life Quality Index (C -DLQI) w ill 
be completed by [CONTACT_148298] 12/ET visits prior to any Investigator assessments to not impact the subject’s answers to the quality of life questionnaire.  
11.3 Skin Oiliness Scale Questionnaire (SOS)  
A facial skin oiliness questionnaire will be completed by [CONTACT_423] 18 years of age and older with moderate facial acne vulgaris and returned at the Baseline and Week 12/ET visits.  
As the questionnaire is only validated in English, only subjects who are native English speakers will 
complete it . 
11.4 Nodules and cysts count  
Nodul es and cysts, if present, will be recorded at each visit . 
12/ ST UDY DRUG DE SCRIPT IO N 
 Investigational Product  Comparator Product  
Trade Name [CONTACT_148299] N/A N/A 
Name [CONTACT_148300]  N/A Vehicle  
Internal Code  CD5789  N/A 
Pharmaceutical Form  Cream  Cream  
Strength/ Concentration  50µg/g  N/A 
Formula number  0219.0102  0219.0082P  
 Packaging (type and 
size) 50 mL bottle with pump and overcap  50 mL bottle with pump and overcap  
 Storage conditions  Store below 25°C (77°F), do not freeze or refrigerate  
 Location of Treated 
Area Face : forehead, nose, chin and right 
and left cheeks  Face : forehead, nose, chin and right 
and left cheeks  
RD.06.SPR.[ADDRESS_170038]  
 Truncal region : right and left 
shoulders, right and left upper anterior 
chest, and right and left upper back;  
reachable to self -application by [CONTACT_1560].  Truncal region : right and left 
shoulders, right and left upper anterior 
chest, and right and left upper back;  
reachable to self -application by [CONTACT_1560]. 
 Route  Topi[INVESTIGATOR_148292]  
 Dose Regimen  Once daily in the evening after 
washing the treated areas  Once daily in the evening after 
washing the treated areas  
 Duration of 
administration  12 Weeks  12 Weeks  
 N/A = Not Applicabl e 
 
RD.06.SPR.[ZIP_CODE]  Protocol summary  
Protocol V03-06Mar2017  
 
 
Page 9 of 10 
Final v ersion dated 10 March  2017 
Schedule of assessments  
 Screening 
Visit 1  
(maximum 
14 days+3 day
s prior to 
Baseline)  Baseline Visit  Week 1  Visit  
(±3 days)  Week 2  Visit 
(±3 days)  Week 4  Visit  
(±3 days)  Week 8  Visit 
(±3 days)  Week  12 
Final/ET Visit2 
(±5 days)  
Informed Consent/ HIPAA (US only )/ PI[INVESTIGATOR_15654] (Canada 
only) and Assent Form/ Photo Consent (selected sites)  X       
Demographics  X X3      
Medical History  X X3      
Previous Therapi[INVESTIGATOR_014]/Procedures  X       
Vital Signs/Physical Examination  X X     X 
Laboratory Safety Test (hematology, chemistry, Urine 
Analysis)  X      X 
Urine Pregnancy Test4 X X3   X X X 
IGA (face)  X X3 X X X X X 
PGA (trunk)5 X X3 X5 X5 X5 X5 X 
Acne Lesion Counting on the Face  X X3 X X X X X 
Acne Lesion Counting on the Trunk5 X X3 X5 X5 X5 X5 X 
Local tolerability on treated areas   X X X X X X 
Photographs (Face and Trunk at selected centers)6  X  X X X X 
Inclusion/Exclusion Criteria3 X X3       
Randomization   X      
Adverse Event recording7 X X X X X X X 
Concomitant Therapi[INVESTIGATOR_014]/Procedures8  X X X X X X 
DLQI or CDLQI9  X     X 
RD.06.SPR.[ZIP_CODE]  Protocol summary  
Protocol V03-06Mar2017  
 
 
Page 10 of 10 
Final v ersion dated 10 March  2017 
 Screening 
Visit 1  
(maximum 
14 days+3 day
s prior to 
Baseline)  Baseline Visit  Week 1  Visit  
(±3 days)  Week 2  Visit 
(±3 days)  Week 4  Visit  
(±3 days)  Week 8  Visit 
(±3 days)  Week  12 
Final/ET Visit2 
(±5 days)  
Skin Oiliness Scale (SOS) Questionnaire11  X     X 
Self-assessment of facial acne improvement        X 
Study drug(s) Dispensing (D) and Accountability (A)   D   D/A D/A A 
Moisturizer/cleanser Dispensing (D)   D10      
Dosing calendar Dispensed (D) returned and reviewed 
(RR)   D RR RR RR RR RR 
Ex it Form11       X 
(1) Baseline v isit must be performed max imum 14  day s after Screening w ith a time w indow  of +[ADDRESS_170039] 14  day s betw een Screening 
and Baseline v isits (for UPT reason).  No re-screening w ill be allow ed.  
(2) Week 12 procedures w ill be performed earlier in case of study  discontinuation.  
(3) Confirm information at Baseline  
(4) For subject of childbearing potential only : Urine Pregnancy  Tests w ill be performed at Screening, Baseline, Week 4, Week 8, W eek 12. For pre-menstrual subjects re -confirm pre -menses 
status at ev ery  v isit and in case of status change collect information on contraceptiv e method and perform a UPT. For the ones w ho begin menses after the Screening v isit, urine 
pregnancy  tests w ill be performed at the v isit w here there w as a change in status and according to the schedule for females of childbearing potential (Baseline, Week 4, 8, 12/ET). 
Additional UPTs may  be performed at the Inv estigator’s discretion.  
(5) Subjects 9 to 11 y ears of age w ho did not meet the criteria for moderate truncal acne at Baseline: PGA w ill be ev aluated after baseline to allow  the inv estigators to decide to start the 
treatment on the trunk if the subject dev elops truncal acne during the study  w hatev er the PGA grade. Local tolerability  w ill be assessed. The Lesion counts w ill not be ev aluated.  
(6) Photos are not mandatory ; subjects w ill be able to participate in the study  ev en if they  refuse to participate in photo proce dures.  
(7) Collection of Adv erse Ev ents w ill begin after signing of the informed consent/assent form.  
(8) Medication that continues after Screening v isit should be recorded on the Concomitant Medication page of the eCRF. Medical or  surgical procedures occurring after Screening v isit should 
be recorded on the Procedures page of the eCRF  
(9) Dermatology  Life Quality  Index  (DLQI) (age 17 and older)/Children’s Dermatology  Life Quality  Index  (C -DLQI) (for 16  y ears and y ounger). If the subject completed a CDLQI at the Baseline 
v isit, a C -DLQI should be completed at the Week 12/ET Visit, regardless  of the subject’s age at the Week 12/ET v isit.  
(10) Subjects w ill be encouraged to use a prov ided or personally  preferred non -comedogenic and hy poallergenic moisturizer liberally  from the Baseline v isit throughout the end of the study .   
(11) The Skin Oiliness Scale (SOS) Questionnaire is only  to be completed by  [CONTACT_1766] w ho are nativ e English speakers. The subject should be prov ided w ith the SOS questionnaire at 
Screening and Week 8, w ith instructions to complete and return it at the Baseline v isit and Week 12 v isit respectiv ely .  
(12) Ex it form should be completed after subject data collection including ev aluation of the laboratory  test results has been completed.  
HIPAA=Health Ins urance Portability and Accountability Act of 1996; PI[INVESTIGATOR_15654]=Pers onal Information Protection and Electronic Documents  Act  